Targeted delivery of anticancer drugs to cancer cells and tissues is a promising field due to
its potential to spare unaffected cells and tissues, but it has been a major challenge to …

Somatostatin (SST), a growth hormone inhibitory peptide, is expressed in endocrine and
non-endocrine tissues, immune cells and the central nervous system (CNS). Post-release …

Breast cancer is one of the leading causes of cancer-associated mortality in women
worldwide and has become a major public health problem. Although the definitive cause of …

Targeted delivery of chemotherapeutics and diagnostic agents conjugated to carrier ligands
has made significant progress in recent years, both in regards to the structural design of the …

Selective targeting to the tumor niche remains a major challenge in successful cancer
therapy. Somatostatin receptor 2 (SSTR2) is overexpressed in breast cancer cells thus …

In this study, a ligand-PEG-lipid conjugate, octreotide-polyethene glycol-deoxycholic acid
(OCT (Phe)-PEG-DOCA, or OPD) was successfully synthesized and used as a targeting …

Lanreotide (LT), a synthetic analog of somatostatin, has been demonstrated to specifically
bind to somatostatin receptors (SSTRs), which are widely overexpressed in several types of …

Peptides are strings of approximately 2–50 amino acids, which have gained huge attention
for theranostic applications in cancer research due to their various advantages including …

Abstract Somatostatin receptors (sst1–5) are present in different types of tumors, where they
inhibit key cellular processes such as proliferation and invasion. Although ssts are densely …

Specifying the exact localization of insulinoma remains challenging due to the lack of
insulinoma-specific imaging methods. Recently, glucagon-like peptide-1 receptor (GLP-1R) …